Top 10 Biotech Angel Investors in Oceania

Last updated: Apr 2024 A list of 10 angel investors that invest in Biotech startups based in Oceania. We rank investors based on the number of investments they made in Biotech companies from Oceania. We update this investor list every month.

Top 10 Biotech Angel Investors in Oceania

Investor	Biotech Oceania investments
Allan Moss	2
Serge van Dam	1
Daniel Petre	1
David Ross	1
Paul Davidson	1
Marko Bogoievski	1
Catherine Lacavera	1
Mike Wallas	1
Latesha Randall	1
Melanie Melanie	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Allan Moss acts an adviser to Anchorage’s Investment Committee. Currently Principal of Allan Moss Investments, a private investment company, Allan retired from the role of Managing Director and Chief Executive Officer of Macquarie Group in May 2008. He was with Macquarie Group for 31 years and served as CEO from 1993 to his retirement in2008. He was also a non- executive director of CSR Ltd from 1996 to 2001.Allan graduated from Sydney University in Arts with a major in Economics and in Laws with Honours. He is also a graduate of Harvard University with a Masters Degree in Business Administration with High Distinction. Allan has received numerous industry awards and recognitions. He was twice named by Barron’s Magazine as one of the 30 most respected CEOs in the world (2006, 2007). He was appointed an Officer of the Order of Australia in 2005.

Investment focus

Health Care, Medical Device, Biotechnology
Funding Round, Series A, Seed
Australia, United States, The Netherlands

Portfolio highlights

Skykraft — Skykraft is an Australian space services firm that specializes in smallsat constellation design, production, and operation.
Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
Invert Robotics — Invert Robotics develops robotic NDT inspection technologies for the maintenance of industrial equipment in the food and beverage, pharmaceutical, and oil and gas industries. Invert Robotics highly skilled team of engineers have developed a world leading modular inspection platform suitable for use across a range of industries and applications.

Serge has a depth of experience in technology startups that is difficult to rival. As CMO of M-Com, Serge led the growth of M-Com from a four person mobile commerce development company to the world's most successful provider of mobile banking and payment solutions (in both licensed and SaaS categories). He has since held executive levelpositions and Directorships, including as Chair on four boards, of many successful B2B SaaS companies. He is also an avid investor.

Investment focus

Biotechnology, Product Research
Seed
New Zealand

Portfolio highlights

Daisy Lab — Daisy Lab pioneers precision fermentation technology in New Zealand

Daniel Petre is the Founder of StartGiving. He was a Founding Chairman and Board Member at Ninemsn. He attended the University of Sydney.

Investment focus

SaaS, Software, Banking
Seed, Pre-Seed, Series A
Australia

Portfolio highlights

Ento — Ento was founded in Australia in 2009 and provides one platform for HR, WFM and engagement. Since then we’ve become the chosen solution for over 3,000 workplaces across retail, hospitality, health, community, and more; rostering more than 30 million shifts for businesses ranging in size from 10 to 2,000+ staff.Our software is part of the nextgeneration of workforce management tools; cloud-based, accessible via a smartphone, tablet or desktop, and integrated with leading ATS, POS and payroll systems to provide a complete solution.
Psylo — Psylo is an Australia-based psychedelic biotech business focusing on Psychedelic-inspired medicine to treat mental illness.
Kismet — Find the best disability or healthcare service to support your journey

David Ross

Investment focus

Biopharma, Biotechnology
Seed
New Zealand

Portfolio highlights

Helico — Helico is developing a proprietary computational platform for synthetic biology research using modelling tools and AI-based prediction algorithms. The long-term aim is to develop a seed bank of different drugs able to be licensed to grow medical supplies in confined greenhouses anywhere in the world.

Paul Davidson joined private equity group, West Coast Capital in 2005 following a successful career in corporate law in the UK, the US and Commonwealth of Independent States. As an active partner in West Coast Capital as well as providing legal counsel, Paul focusses on deal sourcing and transacting.Since joining the group, Paul has successfulyled the acquisition and delisting from the LSE of the UK's largest garden centre business, Wyevale as well as a series of acquisitions and disposals.Prior to joining West Coast Capital headed the corporate team of UK lawyers, McGrigors.In late 1994 Paul was seconded to an oil and gas company called JKX whose focus was on the former Soviet Union, primarily in Ukraine, Georgia and the Russian Federation. JKX listed on the London Stock Exchange in mid 1995 and at that time Paul joined the company as its Legal Director on a full time basis. During his time as Legal Director, Paul gained wide commercial experience as the company concluded a number of transactions throughout the former Soviet Union.

Investment focus

SaaS, FinTech, Privacy
Seed, Series A, Series B
Finland, New Zealand, United Kingdom

Portfolio highlights

Daisy Lab — Daisy Lab pioneers precision fermentation technology in New Zealand
TVSquared — With trusted, independent attribution and partnerships with DSPs, publishers, advertisers and MVPDs, TVSquared measures the effectiveness of TV advertising through an infinitely scalable platform for linear, addressable and OTT/CTV.
Ubisecure — Ubisecure B2B IAM, Legal Entity Identifiers LEI, IDaaS and hybrid identity management. European SSO, MFA, LEI made easy.

Marko retired as CEO of Morrison & Co in 2021 after 13 years of leading the business. He continues to provide guidance for investments in telecommunications and digital infrastructure. His 30 year career has been in the infrastructure and technology sectors in a variety of senior finance, operational and sales roles in the United States and NewZealand. Prior to joining Morrison & Co in 2008, Marko was CFO of Telecom NZ, responsible for corporate finance, M&A and group strategy. Marko is Chair of Vodafone New Zealand.

Investment focus

Biotechnology, Manufacturing
Funding Round
New Zealand

Portfolio highlights

Pictor — Pictor is a biotechnology company develops, manufactures and market immunodiagnostic products.

Catherine Lacavera is the Chief Legal Officer of ShipBob. She previously worked at Color Health as a Chief Legal Officer. Catherine Lacavera attended the University of Toronto.